Literature DB >> 17855699

Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk.

David M Euhus1, Dawei Bu, Raheela Ashfaq, Xian-Jin Xie, Aihua Bian, A Marilyn Leitch, Cheryl M Lewis.   

Abstract

BACKGROUND: Tumor suppressor gene (TSG) methylation is identified more frequently in random periareolar fine needle aspiration samples from women at high risk for breast cancer than women at lower risk. It is not known whether TSG methylation or atypia in nipple duct lavage (NDL) samples is related to predicted breast cancer risk.
METHODS: 514 NDL samples obtained from 150 women selected to represent a wide range of breast cancer risk were evaluated cytologically and by quantitative multiplex methylation-specific PCR for methylation of cyclin D2, APC, HIN1, RASSF1A, and RAR-beta2.
RESULTS: Based on methylation patterns and cytology, NDL retrieved cancer cells from only 9% of breasts ipsilateral to a breast cancer. Methylation of >/=2 genes correlated with marked atypia by univariate analysis, but not multivariate analysis, that adjusted for sample cellularity and risk group classification. Both marked atypia and TSG methylation independently predicted abundant cellularity in multivariate analyses. Discrimination between Gail lower-risk ducts and Gail high-risk ducts was similar for marked atypia [odds ratio (OR), 3.48; P = 0.06] and measures of TSG methylation (OR, 3.51; P = 0.03). However, marked atypia provided better discrimination between Gail lower-risk ducts and ducts contralateral to a breast cancer (OR, 6.91; P = 0.003, compared with methylation OR, 4.21; P = 0.02).
CONCLUSIONS: TSG methylation in NDL samples does not predict marked atypia after correcting for sample cellularity and risk group classification. Rather, both methylation and marked atypia are independently associated with highly cellular samples, Gail model risk classifications, and a personal history of breast cancer. This suggests the existence of related, but independent, pathogenic pathways in breast epithelium.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855699     DOI: 10.1158/1055-9965.EPI-06-1034

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  13 in total

1.  Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.

Authors:  David Euhus; Dawei Bu; Xian-Jin Xie; Venetia Sarode; Raheela Ashfaq; Kelly Hunt; Weiya Xia; Joyce O'Shaughnessy; Michael Grant; Banu Arun; William Dooley; Alexander Miller; David Flockhart; Cheryl Lewis
Journal:  Cancer Prev Res (Phila)       Date:  2011-07-21

2.  Quantitative analysis of promoter methylation in exfoliated epithelial cells isolated from breast milk of healthy women.

Authors:  Chung M Wong; Douglas L Anderton; Sallie Smith-Schneider; Megan A Wing; Melissa C Greven; Kathleen F Arcaro
Journal:  Epigenetics       Date:  2010-10-01       Impact factor: 4.528

3.  Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women.

Authors:  Wenyi Qin; Weizhu Zhu; Huidong Shi; John E Hewett; Rachel L Ruhlen; Ruth S MacDonald; George E Rottinghaus; Yin-Chieh Chen; Edward R Sauter
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

4.  Quantitative evaluation of DNA hypermethylation in malignant and benign breast tissue and fluids.

Authors:  Weizhu Zhu; Wenyi Qin; John E Hewett; Edward R Sauter
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

Review 5.  Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis.

Authors:  Frank A Orlando; Kevin D Brown
Journal:  Ann Surg Oncol       Date:  2009-05-19       Impact factor: 5.344

6.  Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.

Authors:  Mary Jo Fackler; Zoila Lopez Bujanda; Christopher Umbricht; Wei Wen Teo; Soonweng Cho; Zhe Zhang; Kala Visvanathan; Stacie Jeter; Pedram Argani; Chenguang Wang; Jaclyn P Lyman; Marina de Brot; James N Ingle; Judy Boughey; Kandace McGuire; Tari A King; Lisa A Carey; Leslie Cope; Antonio C Wolff; Saraswati Sukumar
Journal:  Cancer Res       Date:  2014-04-15       Impact factor: 12.701

7.  Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer?

Authors:  Jennifer T Loud; Anne C M Thiébaut; Andrea D Abati; Armando C Filie; Kathryn Nichols; David Danforth; Ruthann Giusti; Sheila A Prindiville; Mark H Greene
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-31       Impact factor: 4.254

Review 8.  Mammary ductoscopy in the current management of breast disease.

Authors:  Sarah S K Tang; Dominique J Twelves; Clare M Isacke; Gerald P H Gui
Journal:  Surg Endosc       Date:  2010-12-18       Impact factor: 4.584

9.  A case-control study on risk factors of breast cancer in China.

Authors:  Ya-Li Xu; Qiang Sun; Guang-Liang Shan; Jin Zhang; Hai-Bo Liao; Shi-Yong Li; Jun Jiang; Zhi-Min Shao; Hong-Chuan Jiang; Nian-Chun Shen; Yue Shi; Cheng-Ze Yu; Bao-Ning Zhang; Yan-Hua Chen; Xue-Ning Duan; Bo Li
Journal:  Arch Med Sci       Date:  2012-05-09       Impact factor: 3.318

10.  Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer.

Authors:  Jennifer T Loud; Ellen Burke Beckjord; Kathryn Nichols; June Peters; Ruthann Giusti; Mark H Greene
Journal:  BMC Womens Health       Date:  2009-07-14       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.